Press

2025-02-21

Interim Report Fourth Quarter 2024, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the fourth quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 8,5 million (SEK 17,1 million). Operating loss for the quarter amounted to...

Read More
2024-02-23

Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the fourth quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 17,1 million (SEK 11,6 million). Operating income amounted to SEK -18,5 million (SEK -14,0...

Read More
2023-02-23

Interim Report Fourth Quarter 2022 January 1 – December 31 2022 Kancera AB (publ.), org.nr. 556806-8851

Year in briefOctober – DecemberFinancial summary for the fourth quarter Net sales amounted to SEK 0 million (SEK 0.0 million). R&D costs amounted to SEK 11,6 million (12,9 million). Operating profit for the fourth quarter amounted to SEK -14,0...

Read More
2022-02-18

Interim report for fourth quarter 2021, 1 January – 31 December 2021 Kancera AB (publ.), org.nr. 556806-8851

The year in brief October – DecemberFinancial summary for the fourth quarter Net sales amounted to SEK 0 million (0,0 million). R&D costs amounted to SEK 12,9 million (11,2 million). Operating profit for the fourth quarter amounted to SEK...

Read More
2021-02-19

Interim report for fourth quarter 2020, 1 January – 31 December 2020

Fourth quarter in brief as well as the period 1 January – 31 December 2020 Net sales for the period (January to December) amounted to SEK 0,1 million (3,2 million), of which the fourth quarter contributed SEK 0 million...

Read More
2020-03-02
2019-03-06

Year End Report Kancera AB (publ) 1st January – 31st December 2018

This is a translation of the Year End Report in Swedish published February 20th 2019.

Read More
2018-02-20

YEAR END REPORT KANCERA  AB (publ) 1st January – 31st December 2017

PERIOD 1 JAN – 31 DEC 2017 IN BRIEF • Net turnover for the period amounted to SEK 0.1 million (0.3 million). For the fourth quarter, turnover amounted to 0.0 MEK (0.1 M). • R & D expenses for the period amounted to...

Read More
2017-02-21

INTERIM REPORT FOR KANCERA AB (PUBL) Q4 2016. January 1st – December  31st 2016

THE PERIOD JANUARY – DECEMBER 2016 IN BRIEF R&D expenses for the period amounted to SEK 19,1M (SEK 20,4M) of which the fourth quarter constituted SEK 5.8M (SEK 8,3M). Operating income for the period amounted to SEK -22,3M (SEK -19.7M)...

Read More
2016-02-19

Interim Report for Kancera AB (publ) Q4 2015, January 1 – December 31, 2015

The period January to December 2015 and the fourth quarter 2015 in brief R&D expenses for the period amounted to SEK 20.4m (SEK 13.7m) of which the fourth quarter constituted SEK 8.3m (SEK 4.1m). Following EU’s approval of Kancera’s...

Read More